Please login to the form below

Not currently logged in
Email:
Password:

Robert Freisen joins Ablynx

He will take the role of chief scientific officer, effective March 1

Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities.

He succeeds Dr Antonin de Fougerolles, who left the company last year to become Evox Therapeutics’ chief executive officer.

Freisen has more than 20 years’ experience in the biopharmaceutical industry, leading multiple research and development organisations.

He said: “I have long admired Ablynx and am excited to join the company at such an important time.

“With Ablynx's strong pipeline, platform and technology, I am confident that our talented team will continue to deliver novel products to patients that address unmet medical needs where there are currently limited or no therapeutic options."

He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.

Dr Edwin Moses, chief executive officer of Ablynx, said: “Robert brings an extensive track record of successfully initiating and executing new drug discovery programmes as well as building strong research organisations.

“We are pleased to have him join our team and lead our company's research activities at such an important and exciting time for Ablynx and we will be able to leverage his critical expertise and proven leadership capabilities as we expand our proprietary Nanobody product pipeline.”

31st January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics